Public Health Priorities in India: IMR, NPAFP, Vaccine Sequencing & Cervical Cancer Screening
Examining India's infant mortality rate (IMR), Dr. Jacob Puliyel's NPAFP findings, Peter Aaby's BMJ/Lancet vaccine sequencing research, and the ₹1,300 crore annual HPV vaccine commitment versus India's 1-3% cervical cancer screening coverage.
Key Takeaways
- IMR in India: 6 lakhs children die/annum; Rural IMR remains significantly higher than urban.
- Dr Jacob Puliyel's India's non-polio acute flaccid paralysis (NPAFP) rate was 13.35/100,000 which correlated with pulse polio rounds.
- Aaby's vaccine sequencing research is published in top-tier journals including BMJ, Clinical Infectious Diseases, and Lancet, discussed in Nature, and studied in Maharashtra—but not implemented.
- The government is committing ₹1,300 crore annually to HPV vaccination while India's cervical cancer screening coverage remains 1-3% of eligible women and 71% of districts still report MMR above 140.
- Screening alone (VIA, Pap smear, HPV DNA testing) has reduced cervical cancer mortality by 70-80% in countries that implemented it, whereas a vaccine does not prevent all cervical cancer.
1. IMR in India : 6 lakhs children die/annum 2. Dr Jacob puliyal's India's non-polio acute flaccid paralysis (NPAFP) rate was 13.35/100,000 which correlated with pulse polio rounds.
3. Aaby's Vaccine Sequencing Research
Aaby's vaccine sequencing research is published in top-tier journals including BMJ, Clinical Infectious Diseases, and Lancet & has been discussed in Nature, endorsed by WHO expert committees, and studied across multiple sub-Saharan African populations and in India (Maharashtra). BUT NOT IMPLEMENTED.
4. The HPV Vaccination Rollout Itself Tells Its Own Story
The government is committing ₹1,300 crore annually to HPV vaccination while:
- India's cervical cancer screening coverage remains 1-3% of eligible women.
- 71% of districts still report MMR above 140 (twice the SDG target).
- Rural IMR remains significantly higher than urban.
- Screening alone (VIA, Pap smear, HPV DNA testing) has reduced cervical cancer mortality by 70-80% in countries that implemented it but vaccine does not prevent CC.
What Is Not Proven But Is Reasonable To Infer
A government facing 625,000 infant deaths per year choosing to prioritize ₹1,300 crore on a vaccine that cannot eliminate cervical cancer, while basic maternal-child healthcare infrastructure remains inadequate, suggests the priority-setting process is influenced by factors other than public health optimization. The Gates Foundation's dual role as GAVI funder and as interlocutor with India's PM creates a structural channel through which commercial vaccine interests can be presented as humanitarian imperatives.
Dr. Sujata Mittal, Senior Surgical & Gynaecologic Oncologist, Preventive Oncology Advocate, Famicare Speciality Center, Rohini
Frequently Asked Questions
How effective is cervical cancer screening compared to vaccination alone?
Screening alone (VIA, Pap smear, HPV DNA testing) has reduced cervical cancer mortality by 70-80% in countries that implemented it, whereas the HPV vaccine alone does not prevent all cervical cancers.
What is India's current cervical cancer screening coverage?
India's cervical cancer screening coverage remains only 1-3% of eligible women, even as ₹1,300 crore annually is committed to HPV vaccination.
References
Prioritize evidence-based preventive screening: book a clinical Pap smear, HPV DNA test, or Colposcopy with Dr. Sujata Mittal at Famicare Speciality Center, Rohini.
Related Articles & Latest Clinical Guides
Continue exploring evidence-based oncology, cervical cancer prevention, and wellness insights.
Integrative MedicineInsulin Resistance and PCOS in Young Girls: How Late Nights and Fast Food Rewrite Hormones
Polycystic ovary syndrome (PCOS) affects one in ten women worldwide, with insulin resistance sitting at its core—even in lean teenage girls. Discover how circadian misalignment and modern diets disrupt the HPO axis and how ancient lifestyle wisdom can help reset it.
Cancer CareAdvanced Lung Cancer (Stage IV & SCLC): Targeted Therapies, ADCs & T-Cell Engagers
Metastatic lung cancer is no longer an immediate death sentence. Discover how precision kinase inhibitors, antibody-drug conjugates (ADCs), and bispecific T-cell engagers are transforming Stage IV NSCLC and Small Cell Lung Cancer into manageable chronic conditions.
Cancer CareLung Cancer Treatment (Early Stages I to III): Molecular Biomarkers, Surgery & PACIFIC Protocol
Lung cancer management has transformed. From mandatory multi-gene biomarker panels to robotic lobectomy and perioperative immunotherapy, understand how Stage I to III lung cancer is treated today with curative intent.